Statins as neuroprotectants: A comparative in vitro study of lipophilicity, blood-brain-barrier penetration, lowering of brain cholesterol, and decrease of neuron cell death

Journal of Alzheimer's Disease

Volumn 23, Issue 2, 2011, Pages 307-318

  Sierra, Saleta ^a   Ramos, Maria C ^a   Molina, Pilar ^a   Esteo, Cynthia ^a   Vázquez, Jose Antonio ^a   Burgos, Javier S ^a  

^a BioPharma Division   (Spain)

Author keywords

Blood brain barrier; cholesterol; HMG CoA reductase; in vitro; neuroprotection; okadaic acid; statins

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; COMPACTIN; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; MONACOLIN J; OKADAIC ACID; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; TAU PROTEIN;

ARTICLE; BLOOD BRAIN BARRIER; CELL DEATH; CONTROLLED STUDY; DRUG INHIBITION; DRUG SAFETY; DRUG STRUCTURE; GLIA; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; IN VITRO STUDY; LIPOPHILICITY; LIVER CELL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROMODULATION; NEUROPROTECTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION;

EID: 79951567907     PISSN: 13872877     EISSN: None     Source Type: Journal    
DOI: 10.3233/JAD-2010-101179     Document Type: Article

References (51)

1. Martins IJ, Berger T, Sharman MJ, Verdile G, Fuller SJ, Martins RN (2009) Cholesterol metabolism and transport in the pathogenesis of Alzheimer's disease. J Neurochem 111, 1275-1308.
2. Zambon D, Quintana M, Mata P, Alonso R, Benavent J, Cruz- Sanchez F, Gich J, Pocovi M, Civeira F, Capurro S, Bachman D, Sambamurti K, Nicholas J, Pappolla MA (2010) Higher incidence of mild cognitive impairment in familial hypercholesterolemia. Am J Med 123, 267-274.
3. Tan ZS, Seshadri S, Beiser A, Wilson PW, Kiel DP, Tocco M, D'Agostino RB, Wolf PA (2003) Plasma total cholesterol level as a risk factor for Alzheimer disease: the Framingham Study. Arch Intern Med 163, 1053-1057. (Pubitemid 36548931)
4. Puglielli L, Tanzi RE, Kovacs DM (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci 6, 345-351. (Pubitemid 36373979)
5. Pappolla MA, Bryant-Thomas TK, Herbert D, Pacheco J, Fabra Garcia M, Manjon M, Girones X, Henry TL, Matsubara E, Zambon D, Wolozin B, Sano M, Cruz- Sanchez FF, Thal LJ, Petanceska SS, Refolo LM (2003) Mild hypercholesterolemia is an early risk factor for the development of Alzheimer amyloid pathology. Neurology 61, 199-205. (Pubitemid 36875301)
6. Refolo LM, Malester B, LaFrancois J, Bryant-Thomas T, Wang R, Tint GS, Sambamurti K, Duff K, Pappolla MA (2000) Hypercholesterolemia accelerates the Alzheimer's amyloid pathology in a transgenic mouse model. Neurobiol Dis 7, 321-331.
7. Shie FS, Jin LW, Cook DG, Leverenz JB, LeBoeuf RC (2002) Diet-induced hypercholesterolemia enhances brain A beta accumulation in transgenic mice. Neuroreport 13, 455-459. (Pubitemid 34293189)
8. Refolo LM, Pappolla MA, LaFrancois J, Malester B, Schmidt SD, Thomas-Bryant T, Tint GS, Wang R, Mercken M, Petanceska SS, Duff KE (2001) A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 8, 890-899. (Pubitemid 33055603)
9. Fassbender K, Stroick M, Bertsch T, Ragoschke A, Kuehl S, Walter S,Walter J, Brechtel K, Muehlhauser F,Von Bergmann K, Lutjohann D (2002) Effects of statins on human cerebral cholesterol metabolism and secretion of Alzheimer amyloid peptide. Neurology 59, 1257-1258. (Pubitemid 35192402)
10. Wolozin B, Manger J, Bryant R, Cordy J, Green RC, McKee A (2006) Re-assessing the relationship between cholesterol, statins and Alzheimer's disease. Acta Neurol Scand Suppl 185, 63-70. (Pubitemid 44015227)
11. Li G, Shofer JB, Rhew IC, Kukull WA, Peskind ER, McCormick W, Bowen JD, Schellenberg GD, Crane PK, Breitner JC, Larson EB (2010) Age-varying association between statin use and incident Alzheimer's disease. J Am Geriatr Soc 58, 1311-1317.
12. Rockwood K, Kirkland S, Hogan DB, MacKnight C, Merry H, Verreault R, Wolfson C, McDowell I (2002) Use of lipid-lowering agents, indication bias, and the risk of dementia in community-dwelling elderly people. Arch Neurol 59, 223-227. (Pubitemid 34240938)
13. Jick H, Zornberg GL, Jick SS, Seshadri S, Drachman DA (2000) Statins and the risk of dementia. Lancet 356, 1627-1631.
14. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, Schwam E, Schindler R, Hey-Hadavi J, DeMicco DA, Breazna A (2010) Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. Neurology 74, 956-964.
15. Hyttinen L, Tuulio-Henriksson A, Vuorio AF, Kuosmanen N, Harkanen T, Koskinen S, Strandberg TE (2010) Longterm statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls. J Alzheimers Dis, Epub ahead of print.
16. Wolozin B, Brown J 3rd, Theisler C, Silberman S (2004) The cellular biochemistry of cholesterol and statins: insights into the pathophysiology and therapy of Alzheimer's disease. CNS Drug Rev 10, 127-146. (Pubitemid 38879107)
17. Saher G, Brugger B, Lappe-Siefke C, Mobius W, Tozawa R, Wehr MC, Wieland F, Ishibashi S, Nave KA (2005) High cholesterol level is essential for myelin membrane growth. Nat Neurosci 8, 468-475. (Pubitemid 41007564)
18. Funfschilling U, Saher G, Xiao L, MobiusW, NaveKA(2007) Survival of adult neurons lacking cholesterol synthesis in vivo. BMC Neurosci 8, 1.
19. Danik M, Champagne D, Petit-Turcotte C, Beffert U, Poirier J (1999) Brain lipoprotein metabolism and its relation to neurodegenerative disease. Crit Rev Neurobiol 13, 357-407.
20. Mauch DH, Nagler K, Schumacher S, Goritz C, Muller EC, Otto A, Pfrieger FW (2001) CNS synaptogenesis promoted by glia-derived cholesterol. Science 294, 1354-1357. (Pubitemid 33063104)
21. Duggan DE, Vickers S (1990) Physiological disposition of HMG-CoA-reductase inhibitors. Drug Metab Rev 22, 333-362. (Pubitemid 20340903)
22. Roth BD, Bocan TM, Blankley CJ, ChucholowskiAW, Creger PL, CreswellMW, Ferguson E, Newton RS, O'Brien P, Picard JA, et al. (1991) Relationship between tissue selectivity and lipophilicity for inhibitors of HMG-CoA reductase. J Med Chem 34, 463-466.
23. Di L, Kerns EH, Fan K, McConnell OJ, Carter GT (2003) High throughput artificial membrane permeability assay for blood-brain barrier. Eur J Med Chem 38, 223-232. (Pubitemid 36349665)
24. Wexler DS, Gao L, Anderson F,OwA, Nadasdi L, McAlorum A, Urfer R, Huang SG (2005) Linking solubility and permeability assays for maximum throughput and reproducibility. J Biomol Screen 10, 383-390. (Pubitemid 40800567)
25. Wohnsland F, Faller B (2001) High-throughput permeability pH profile and high-throughput alkane/water log P with artificial membranes. J Med Chem 44, 923-930. (Pubitemid 32861617)
26. Holdgate GA, Ward WH, McTaggart F (2003) Molecular mechanism for inhibition of 3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reductase by rosuvastatin. Biochem Soc Trans 31, 528-531. (Pubitemid 36750725)
27. Hozumi Y, Kawano M, Jordan VC (2000) In vitro study of the effect of raloxifene on lipid metabolism compared with tamoxifen. Eur J Endocrinol 143, 427-430.
28. GambleW,Vaughan M, Kruth HS,Avigan J (1978) Procedure for determination of free and total cholesterol in micro- or nanogram amounts suitable for studies with cultured cells. J Lipid Res 19, 1068-1070. (Pubitemid 9059821)
29. Mizoguchi T, Edano T, Koshi T (2004) A method of direct measurement for the enzymatic determination of cholesteryl esters. J Lipid Res 45, 396-401. (Pubitemid 38228838)
30. Kikkawa R, Yamamoto T, Fukushima T, Yamada H, Horii I (2005) Investigation of a hepatotoxicity screening system in primary cell cultures - "what biomarkers would need to be addressed to estimate toxicity in conventional and new approaches?". J Toxicol Sci 30, 61-72. (Pubitemid 40410215)
31. Sun X, Cole GM, Chu T, Xia W, Galasko D, Yamaguchi H, Tanemura K, Frautschy SA, TakashimaA(2002) Intracellular Abeta is increased by okadaic acid exposure in transfected neuronal and non-neuronal cell lines. Neurobiol Aging 23, 195-203. (Pubitemid 34137093)
32. Xing C, Peng Y, Chang R, Yin Y, Xie Z (2005) Effects of insulin-like growth factor-1 on okadaic acid-induced apoptosis in SH-SY5Y cells. Cell Biol Int 29, 803-808. (Pubitemid 41558172)
33. DeKosky ST (2005) Statin therapy in the treatment of Alzheimer disease: what is the rationale?AmJ Med 118(Suppl 12A), 48-53.
34. Austen B, Christodoulou G, Terry JE (2002) Relation between cholesterol levels, statins and Alzheimer's disease in the human population. J Nutr Health Aging 6, 377-382. (Pubitemid 36024781)
35. Wolozin B, Kellman W, Ruosseau P, Celesia GG, Siegel G (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57, 1439-1443.
36. Yaffe K, Barrett-Connor E, Lin F, Grady D (2002) Serum lipoprotein levels, statin use, and cognitive function in older women. Arch Neurol 59, 378-384. (Pubitemid 34208144)
37. Wolozin B, Wang SW, Li NC, Lee A, Lee TA, Kazis LE (2007) Simvastatin is associated with a reduced incidence of dementia and Parkinson's disease. BMC Med 5, 20.
38. Reinoso RF, Sanchez Navarro A, Garcia MJ, Prous JR (2002) Preclinical pharmacokinetics of statins. Methods Find Exp Clin Pharmacol 24, 593-613. (Pubitemid 36109399)
39. Ertl P, Rohde B, Selzer P (2000) Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J Med Chem 43, 3714-3717.
40. Serajuddin AT, Ranadive SA, Mahoney EM (1991) Relative lipophilicities, solubilities, and structure-pharmacological considerations of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitors pravastatin, lovastatin, mevastatin, and simvastatin. J Pharm Sci 80, 830-834.
41. Botti RE, Triscari J, Pan HY, Zayat J (1991) Concentrations of pravastatin and lovastatin in cerebrospinal fluid in healthy subjects. Clin Neuropharmacol 14, 256-261.
42. Haag MD, Hofman A, Koudstaal PJ, Stricker BH, Breteler MM (2009) Statins are associated with a reduced risk of Alzheimer disease regardless of lipophilicity. The Rotterdam Study. J Neurol Neurosurg Psychiatry 80, 13-17.
43. Stolp HB, Dziegielewska KM (2009) Review: role of developmental inflammation and blood-brain barrier dysfunction in neurodevelopmental and neurodegenerative diseases. Neuropathol Appl Neurobiol 35, 132-146.
44. Hoglund K, Blennow K (2007) Effect of HMG-CoA reductase inhibitors on beta-amyloid peptide levels: implications for Alzheimer's disease. CNS Drugs 21, 449-462. (Pubitemid 46849181)
45. Lukiw WJ (2008) Emerging amyloid beta (Ab) peptide modulators for the treatment of Alzheimer's disease (AD). Expert Opin Emerg Drugs 13, 255-271. (Pubitemid 351957348)
46. Ehehalt R, Keller P, Haass C, Thiele C, Simons K (2003) Amyloidogenic processing of the Alzheimer beta-amyloid precursor protein depends on lipid rafts. J Cell Biol 160, 113-123. (Pubitemid 36091721)
47. Simons K, Ehehalt R (2002) Cholesterol, lipid rafts, and disease. J Clin Invest 110, 597-603. (Pubitemid 34988781)
48. Kirsch C, Eckert GP, Mueller WE (2003) Statin effects on cholesterol micro-domains in brain plasma membranes. Biochem Pharmacol 65, 843-856. (Pubitemid 36293701)
49. Volpe JJ, Hennessy SW (1977) Cholesterol biosynthesis and 3-hydroxy-3-methyl-glutaryl coenzyme A reductase in cultured glial and neuronal cells. Regulation by lipoprotein and by certain free sterols. Biochim Biophys Acta 486, 408-420. (Pubitemid 8054524)
50. Roensch J, Crisby M, Nordberg A, Xiao Y, Zhang LJ, Guan ZZ (2007) Effects of statins on alpha7 nicotinic receptor, cholinesterase and alpha-form of secreted amyloid precursor peptide in SH-SY5Y cells. Neurochem Int 50, 800-806. (Pubitemid 46710193)
51. Riekse RG, Li G, Petrie EC, Leverenz JB, Vavrek D, Vuletic S, Albers JJ, Montine TJ, Lee VM, Lee M, Seubert P, Galasko D, Schellenberg GD, Hazzard WR, Peskind ER (2006) Effect of statins on Alzheimer's disease biomarkers in cerebrospinal fluid. J Alzheimers Dis 10, 399-406.